Bayer Moves Forward with Settlement in Roundup Case

Bayer is advancing a U.S. class settlement to address claims that its Roundup weedkiller causes non-Hodgkin lymphoma. CEO Bill Anderson highlights the settlement's significance to its Supreme Court case, aiming to minimize legal risks.

Bayer announced a settlement in the U.S. to address ongoing and future claims that Roundup weedkiller is linked to non-Hodgkin lymphoma. Bayer CEO Bill Anderson emphasized its importance to the company's ongoing Supreme Court battle.

Anderson stated the settlement minimizes legal risks, as it forms a critical part of the case presented to the Supreme Court.

He noted both the settlement and the Supreme Court case as independently crucial components that strengthen Bayer's legal strategy.

(With inputs from agencies.)